ADCs Returned 0.46 in Relapsed Disease and 1.15 in the Front Line at WCLC
The dividing line is not the target or the payload. It is the setting: relapsed disease against chemotherapy, or the front line against chemo-IO.
DealPulse Signal
The Beats
Analysis
The Briefs
Axon Targeting’s Switch Lives in the Cell Body Observed Here, Not Operated
NICE Withdrew Four Appraisals Because the Medicine Went Off Patent.
CMS Added Five Tracks to ACCESS. The Payer Pledge Covers 165 Million People Who Cannot Join It.
The UK Commission Wants L-Plates for AI and an End to One-Time Approval
Lilly Confirmed the Calculations Were Wrong. A Jury Is Deciding What That Cost Nektar.
